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HTA will not be the appropriate instrument for its own,
but should be used in combination with comprehensive
HTA.
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The time inconsistency of decisions (TID) is the phenom-
enon, studied in various domains of economics, when a
decision is optimal from the perspective of one moment
in time and ceases being so in a subsequent moment.
OBJECTIVES: The aim of the study was to check for the
feasibility of prevailing of the TID in the pharmacoeco-
nomic sequential decision problems as well as to identify
the impact of this phenomenon on the process of decision
implementation and its outcomes. METHODS: A formal
model of sequential decision problems, both with and
without uncertainty, based on a graph theory, was pro-
vided. In such a framework the decision problem is rep-
resented by a graph and a set of functions over the vertices
representing the costs, effects and the probability distrib-
utions; decision alternatives are subgraphs; alternatives
are described by the expected values of costs and effects;
the rule of choice is to minimize criterion function of the
expected cost and effectiveness, representing the prefer-
ences of a decision maker. The ﬂow of time can be mod-
elled by analyzing subsequent decision problems, called
reduced problems, being the subgraphs of the original
problem obtained by cutting the original graph in a
certain vertex. RESULTS: There exist criteria susceptible
to TID phenomenon, in particular the cost-effectiveness
criterion is susceptible to TID in problems both with and
without uncertainty and cost-beneﬁt criterion or incre-
mental cost-effectiveness criterion are resistant to TID in
these kinds of problems. TID can lead actual decision
makers to behave differently than advised accordingly to
the model solutions and can make them choose actions
that lead to pareto-nonoptimal decisions. CONCLU-
SIONS: The TID is immanently present in pharmaco-
economic decision problems as the widely used
cost-effectiveness criterion is susceptible to it. It causes
ambiguities in decision problem solving as the actual deci-
sion maker(s) may not stick to the model solution in a
real life. The effect of this phenomenon can be pareto-
nonoptimal behaviour.
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OBJECTIVE: Hip fracture has long been associated with
signiﬁcantly increased morbidity as well as mortality. It is
argued that the currently available methodological guid-
ance on cost assessment falls short of distinguishing
between costs associated with a hip fracture and costs
associated with “old age”. METHODS: It is suggested
that additional insight into this question can be gained by
linking data on a patient’s resource consumption with his
or her outcomes data: In order to establish that costs were
directly attributable to the sustained hip fracture, they
needed to be accompanied by corresponding changes in
physical functioning, and changes in physical functioning
which the patient might associate with the sustained hip
fracture rather than “old age”. An analysis of the incre-
mental health and social care costs associated with 449
hip fractures in Tayside, Scotland (UK) in the year fol-
lowing the fracture suggests that in only a minority of
patients did long-term costs due to changes in accommo-
dation needs coincide with a decline in physical func-
tioning. RESULTS: Even fewer patients attributed any
changes that did occur in this respect to the sustained
fracture. Taking outcomes data into account thus reduced
the costs, which can be directly attributed to a hip frac-
ture by 40% in this patient group. CONCLUSIONS: The
data of this patient group thus appears to suggest that
cost estimates of hip fracture based on current method-
ologies of cost assessment are overestimating the real
costs of the condition by 40%.
METHODOLOGICAL ISSUES—Modeling
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OBJECTIVES: The few decision analytic models of glau-
coma treatment that exist have focused on absolute
reduction (in mmHg) of intraocular pressure (IOP) rather
than achievement of target IOP, which varies greatly 
by patient. We provide an overview of an innovative 
glaucoma model and highlight important modeling 
challenges. METHODS: A simulation model of the man-
agement of patients with open-angle glaucoma and/or
ocular hypertension was developed in Microsoft Excel.
The model examined competing strategies involving
sequential use of up to six interventions with switches
based on the monthly probability that a patient was “suc-
cessfully maintained” on therapy. These probabilities
were based on discontinuation data from actual clinical
practice. Therapy discontinuation could be due to lack of
IOP control, adverse events, or lack of compliance/
persistence. Outputs of the model include months of
treatment, switching frequency, days of IOP control, 
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frequency of ophthalmologist visits, probability of
surgery and total costs. The user can specify country-
speciﬁc treatment strategies, therapy discontinuation, sur-
gical rates, practice patterns and costs. RESULTS: The
key challenges included: selection of a disease outcome
that was relevant to current clinical practice; choice of
time horizon; incorporation of therapy discontinuation;
reﬂection of diversity in treatment options; and consider-
ation of variability in patient response. CONCLUSIONS:
Modeling the clinical and economic impacts of glaucoma
treatment involve challenges shared with other chronic
diseases where the deﬁnition of treatment success is
patient-speciﬁc. The model offers insights into accommo-
dating patient-speciﬁc variability through the use of per-
sistence distributions from actual clinical practice. The
model provides a clinically relevant tool for decision-
makers and clinicians to assess management strategies for
glaucoma.
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OBJECTIVE: To develop a generic decision-analytic
model for the evaluation of long-term clinical and eco-
nomic consequences of interventions in patients with
Parkinson’s disease (PD) which can be applied to differ-
ent research questions, interventions, and outcomes, 
and is based on (untreated) biological progression.
METHODS: We developed a Markov model, in which a
hypothetical cohort of patients moves through health
states reﬂecting patient characteristics that are observed
under treatment (Hoehn and Yahr “on” state [HYon])
and would be observed in the absence of treatment
(Hoehn and Yahr “off” state [HYoff]). We used HYoff
I–V s as Markov states, because those reﬂect underlying
biologic progression of PD. Interventions: diagnostic or
treatment strategies in PD patients such as Levodopa,
dopamine agonists, or other anti-parkinsonian drugs as
well as surgical therapies such as deep brain stimulation.
Data: Transition probabilities for HYoff states were
derived from the literature. The distribution of HYon 
was modeled conditional on HYoff using studies that
report both characteristic. Complications were modeled
conditional on HYon using data from a registry estab-
lished by the “Competence Network Parkinson Disease”.
Utilities, and costs were modeled conditional on HYon
and presence of complication. Mortality is a function 
of age- and gender-speciﬁc background mortality and PD-
speciﬁc mortality Time horizon: lifetime with annual
cycle length. RESULTS: Remaining (quality-adjusted) 
life expectancy, direct costs, and incremental cost-
effectiveness ratios. Further outcomes comprise clinical
events or complications such as motor complications,
dementia, depression, and hallucinations. In addition,
complication-free survival, time in HYoff and HYon
states, and UPDRS scores were modeled as additional
outcomes. Perspective: societal and third party payer. 
Sensitivity analysis: 1-way and multiway. An interactive
interface allows to model different settings or countries.
CONCLUSIONS: In contrast to formerly published
models, this generic PD model has the ability to consider
multiple interventions and outcomes and to switch
between outcomes depending on which outcomes are
reported in a clinical trial.
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OBJECTIVES: The most wide-spread acid-related disor-
ders are peptic ulcer disease (PUD) and gastroesophageal
reﬂux (GERD). The literature indicates that during past
years PUD had been diagnosed less frequently, whereas
GERD had been diagnosed more often. Our study aimed
at modelling the prevalence of PUD and GERD using
claims data of a major sickness fund. The second aim was
to quantify the drug expenditures for acid-related disor-
ders and to analyse the outcomes of eradication therapy
under non-interventional routine treatment conditions.
METHODS: On the basis of prescription records from
2000 and 2001, insured persons were classiﬁed as GERD
or PUD patients according to typical prescription pat-
terns, to the diagnoses of sick leave periods and hospi-
talisations. According to this classiﬁcation, the prevalence
of acid-related disorders was modelled. Outcomes were
analysed by comparing hospitalisations, sick leave
periods and costs in groups with and without eradication
therapy. RESULTS: From a total of 1,408,902 insured
persons 134,759 had at least one antacid prescription.
With regard to the deﬁned prescription patterns we esti-
mated a 2-year treatment prevalence of 3.93% and
3.77% for PUD and GERD, respectively. Within the 2-
year period, drug expenditures for the treatment of acid-
related disorders added up to €5.9 and €8.1 million,
respectively. For 5,926 out of 41,301 people assumed to
suffer from PUD, an eradication therapy could be
detected. In groups without eradication therapy the risk
for hospitalisation or sick leave periods was twice as high
as in groups with eradication therapy. Hospitalisation
costs were considerably higher, too. CONCLUSIONS:
Although eradication therapy was found to reduce the
risk for hospitalisation, sick leave periods and costs, this
therapeutic approach was practised only for a minor pro-
portion of patients suffering from PUD. Our ﬁndings
suggest that there is still room for diagnostic and thera-
peutic improvement in the management of acid-related
disorders.
